140 pounds lost on GLP-1s: what the science says about extreme weight loss claims

What's this video probably claiming?

Based on the caption '140 LBS gone forever' and the #glp1community hashtag, @lizdamyl is almost certainly sharing a personal weight loss transformation story attributed to GLP-1 receptor agonist therapy, likely semaglutide (Wegovy/Ozempic) or tirzepatide (Zepbound/Mounjaro). A 140-pound loss is a significant, outlier-level result that will land with a community hungry for hope, which is exactly why it gets 103.8K views. The 'gone forever' framing is where things get scientifically dicey. That phrase implies permanence, and that's a claim the clinical literature does not support without significant caveats. This video likely also touches on the lifestyle changes alongside medication, dosing timelines, and possibly a before-and-after comparison. None of that is inherently harmful, but without context around how long this took, what dose, and what happens when the drug stops, the story is incomplete in ways that matter.

What does the science actually show?

GLP-1 receptor agonists produce real, clinically meaningful weight loss, but 140 pounds represents an outcome well above what trials typically report as an average. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed tirzepatide at 15mg produced a mean body weight reduction of 20.9% over 72 weeks. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide 2.4mg produced a mean reduction of 14.9% of body weight. For someone starting at, say, 340 pounds, a 140-pound loss would represent roughly 41% of body weight, far outside those averages. That does not make it impossible. Trials report means, not ceilings, and individual responses vary considerably. However, results this extreme likely also involve significant dietary changes, exercise, behavioral interventions, or extended treatment duration, factors that rarely get the same caption space as the drug itself.

Where does the social media noise diverge from clinical reality?

The phrase 'gone forever' is doing a lot of heavy lifting here. The STEP 4 trial (Rubino et al., 2021, JAMA) is the one creators in this space should be required to read before posting. Participants who discontinued semaglutide after 20 weeks regained approximately two-thirds of their lost weight within one year. The SURMOUNT-4 trial (Aronne et al., 2024, JAMA) showed similar weight regain patterns after tirzepatide discontinuation. Weight loss on GLP-1s appears to require ongoing treatment for the majority of patients, not a fixed course. GLP-1 receptors are involved in appetite regulation in ways that persist beyond the treatment window only if the underlying physiological changes are maintained. Social media frames these drugs as a one-time fix. The clinical picture is closer to a chronic disease management model, which is a meaningfully different conversation to have with 103.8K viewers.

What should you actually know?

A 140-pound loss is real and worth celebrating. But the context around it matters enormously for anyone watching this video and wondering if GLP-1 therapy could do the same for them. Results this significant typically emerge over 12 to 24 months or longer, not a single treatment cycle. Side effects including nausea, vomiting, gastroparesis risk, and pancreatitis concerns are real and documented. The SCALE trial program (Pi-Sunyer et al., 2015, NEJM) with liraglutide and subsequent semaglutide trials consistently show that adverse events lead to discontinuation in a meaningful percentage of patients. Anyone considering GLP-1 therapy should do so under medical supervision with realistic expectations about average outcomes, not outlier transformations. Compounded versions of these drugs carry additional considerations around consistency and dosing accuracy that are not interchangeable with FDA-approved formulations.